Advice
following a full submission
aripiprazole prolonged release suspension for injection (Abilify Maintena®) is accepted for use within NHS Scotland.
Indication under review: maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.
In a comparative study, aripiprazole prolonged release suspension for injection was as effective as oral aripiprazole in reducing the risk of impending relapse over 26 weeks in stabilised schizophrenic patients. Weaknesses in the indirect comparison limit the reliability of relative efficacy and safety with prolonged release injection forms of other atypical antipsychotics.
Download detailed advice182KB (PDF)
Medicine details
- Medicine name:
- aripiprazole (Abilify)
- SMC ID:
- 962/14
- Indication:
- Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.
- Pharmaceutical company
- Otsuka Pharmaceutical Europe
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 May 2014